vs
Side-by-side financial comparison of Clear Channel Outdoor Holdings, Inc. (CCO) and Guardant Health, Inc. (GH). Click either name above to swap in a different company.
Clear Channel Outdoor Holdings, Inc. is the larger business by last-quarter revenue ($461.5M vs $281.3M, roughly 1.6× Guardant Health, Inc.). Clear Channel Outdoor Holdings, Inc. runs the higher net margin — 1.7% vs -45.7%, a 47.4% gap on every dollar of revenue. On growth, Guardant Health, Inc. posted the faster year-over-year revenue change (39.4% vs 8.2%). Clear Channel Outdoor Holdings, Inc. produced more free cash flow last quarter ($30.3M vs $-54.2M). Over the past eight quarters, Guardant Health, Inc.'s revenue compounded faster (29.2% CAGR vs 18.8%).
Clear Channel Outdoor Holdings, Inc. is a multinational corporation focused on outdoor advertising. The company is based in San Antonio, Texas.
Guardant Health, Inc. is an American biotechnology company based in Palo Alto, California. Co-founders Helmy Eltoukhy and AmirAli Talasaz serve as co-chief executive officers.
CCO vs GH — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $461.5M | $281.3M |
| Net Profit | $8.0M | $-128.5M |
| Gross Margin | — | 64.6% |
| Operating Margin | 23.3% | -43.0% |
| Net Margin | 1.7% | -45.7% |
| Revenue YoY | 8.2% | 39.4% |
| Net Profit YoY | 144.8% | -15.8% |
| EPS (diluted) | $0.01 | $-1.01 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $461.5M | $281.3M | ||
| Q3 25 | $405.6M | $265.2M | ||
| Q2 25 | $402.8M | $232.1M | ||
| Q1 25 | $334.2M | $203.5M | ||
| Q4 24 | $426.7M | $201.8M | ||
| Q3 24 | $375.2M | $191.5M | ||
| Q2 24 | $376.5M | $177.2M | ||
| Q1 24 | $326.8M | $168.5M |
| Q4 25 | $8.0M | $-128.5M | ||
| Q3 25 | $-60.1M | $-92.7M | ||
| Q2 25 | $9.5M | $-99.9M | ||
| Q1 25 | $62.5M | $-95.2M | ||
| Q4 24 | $-17.9M | $-111.0M | ||
| Q3 24 | $-32.5M | $-107.8M | ||
| Q2 24 | $-39.2M | $-102.6M | ||
| Q1 24 | $-89.7M | $-115.0M |
| Q4 25 | — | 64.6% | ||
| Q3 25 | — | 64.7% | ||
| Q2 25 | — | 65.0% | ||
| Q1 25 | — | 63.3% | ||
| Q4 24 | — | 61.6% | ||
| Q3 24 | — | 61.1% | ||
| Q2 24 | — | 59.1% | ||
| Q1 24 | — | 61.2% |
| Q4 25 | 23.3% | -43.0% | ||
| Q3 25 | 19.9% | -37.3% | ||
| Q2 25 | 19.2% | -45.9% | ||
| Q1 25 | 13.5% | -54.6% | ||
| Q4 24 | 23.5% | -62.4% | ||
| Q3 24 | 17.8% | -61.3% | ||
| Q2 24 | 18.2% | -56.8% | ||
| Q1 24 | 13.4% | -59.2% |
| Q4 25 | 1.7% | -45.7% | ||
| Q3 25 | -14.8% | -35.0% | ||
| Q2 25 | 2.4% | -43.0% | ||
| Q1 25 | 18.7% | -46.8% | ||
| Q4 24 | -4.2% | -55.0% | ||
| Q3 24 | -8.7% | -56.3% | ||
| Q2 24 | -10.4% | -57.9% | ||
| Q1 24 | -27.4% | -68.2% |
| Q4 25 | $0.01 | $-1.01 | ||
| Q3 25 | $-0.12 | $-0.74 | ||
| Q2 25 | $0.02 | $-0.80 | ||
| Q1 25 | $0.13 | $-0.77 | ||
| Q4 24 | $-0.03 | $-0.90 | ||
| Q3 24 | $-0.07 | $-0.88 | ||
| Q2 24 | $-0.08 | $-0.84 | ||
| Q1 24 | $-0.19 | $-0.94 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $190.0M | $378.2M |
| Total DebtLower is stronger | $5.1B | $1.5B |
| Stockholders' EquityBook value | $-3.4B | $-99.3M |
| Total Assets | $3.8B | $2.0B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $190.0M | $378.2M | ||
| Q3 25 | $155.0M | $580.0M | ||
| Q2 25 | $138.6M | $629.1M | ||
| Q1 25 | $395.8M | $698.6M | ||
| Q4 24 | $109.7M | $525.5M | ||
| Q3 24 | $201.1M | $585.0M | ||
| Q2 24 | $189.3M | $933.7M | ||
| Q1 24 | $193.2M | $1.0B |
| Q4 25 | $5.1B | $1.5B | ||
| Q3 25 | $5.1B | $1.1B | ||
| Q2 25 | $5.1B | $1.1B | ||
| Q1 25 | $5.3B | $1.1B | ||
| Q4 24 | $5.7B | $1.1B | ||
| Q3 24 | $5.7B | — | ||
| Q2 24 | $5.7B | — | ||
| Q1 24 | $5.7B | — |
| Q4 25 | $-3.4B | $-99.3M | ||
| Q3 25 | $-3.5B | $-354.5M | ||
| Q2 25 | $-3.4B | $-305.5M | ||
| Q1 25 | $-3.4B | $-250.8M | ||
| Q4 24 | $-3.6B | $-139.6M | ||
| Q3 24 | $-3.6B | $-60.1M | ||
| Q2 24 | $-3.6B | $-1.6M | ||
| Q1 24 | $-3.5B | $68.3M |
| Q4 25 | $3.8B | $2.0B | ||
| Q3 25 | $3.8B | $1.3B | ||
| Q2 25 | $3.8B | $1.3B | ||
| Q1 25 | $4.0B | $1.3B | ||
| Q4 24 | $4.8B | $1.5B | ||
| Q3 24 | $4.6B | $1.5B | ||
| Q2 24 | $4.5B | $1.6B | ||
| Q1 24 | $4.6B | $1.7B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $56.3M | $-26.4M |
| Free Cash FlowOCF − Capex | $30.3M | $-54.2M |
| FCF MarginFCF / Revenue | 6.6% | -19.3% |
| Capex IntensityCapex / Revenue | 5.6% | 9.9% |
| Cash ConversionOCF / Net Profit | 7.04× | — |
| TTM Free Cash FlowTrailing 4 quarters | $32.0M | $-233.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $56.3M | $-26.4M | ||
| Q3 25 | $56.2M | $-35.4M | ||
| Q2 25 | $-12.6M | $-60.3M | ||
| Q1 25 | $14.9M | $-62.7M | ||
| Q4 24 | $29.3M | $-64.5M | ||
| Q3 24 | $54.5M | $-51.1M | ||
| Q2 24 | $30.8M | $-94.0M | ||
| Q1 24 | $-34.8M | $-30.3M |
| Q4 25 | $30.3M | $-54.2M | ||
| Q3 25 | $41.4M | $-45.8M | ||
| Q2 25 | $-29.2M | $-65.9M | ||
| Q1 25 | $-10.6M | $-67.1M | ||
| Q4 24 | $-27.8M | $-83.4M | ||
| Q3 24 | $21.0M | $-55.3M | ||
| Q2 24 | $5.2M | $-99.1M | ||
| Q1 24 | $-61.0M | $-37.2M |
| Q4 25 | 6.6% | -19.3% | ||
| Q3 25 | 10.2% | -17.3% | ||
| Q2 25 | -7.2% | -28.4% | ||
| Q1 25 | -3.2% | -33.0% | ||
| Q4 24 | -6.5% | -41.3% | ||
| Q3 24 | 5.6% | -28.9% | ||
| Q2 24 | 1.4% | -55.9% | ||
| Q1 24 | -18.7% | -22.1% |
| Q4 25 | 5.6% | 9.9% | ||
| Q3 25 | 3.7% | 3.9% | ||
| Q2 25 | 4.1% | 2.4% | ||
| Q1 25 | 7.6% | 2.2% | ||
| Q4 24 | 13.4% | 9.4% | ||
| Q3 24 | 8.9% | 2.2% | ||
| Q2 24 | 6.8% | 2.9% | ||
| Q1 24 | 8.0% | 4.1% |
| Q4 25 | 7.04× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -1.32× | — | ||
| Q1 25 | 0.24× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CCO
Segment breakdown not available.
GH
| Oncology | $189.9M | 68% |
| Biopharma Data | $54.0M | 19% |
| Screening | $35.1M | 12% |
| Licensing Other | $2.2M | 1% |
